Durata Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY13 | FY12 | FY11 | |
|---|---|---|---|
| Revenue | $0 | — | — |
| Operating income | −$15.4M | −$8.3M | −$35.6M |
| Net income | −$15.8M | −$8.3M | −$33.0M |
| Total assets | $100.1M | $86.5M | $33.6M |
| Total liabilities | $61.6M | $42.7M | $22.1M |
| Equity | $38.6M | $43.9M | $5.6M |
| EPS (diluted) | — | — | — |
| Shares out. | 18.4M | 18.4M | 62,500 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2013- Operating margin
- —
- Net margin
- —
- Return on equity
- −40.9%
- Return on assets
- −15.7%
- Return on capital (ROCE)
- −17.9%
- Liabilities / assets
- 61.5%
- Debt / equity
- 1.60×
- Book value / share
- $2.10
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2013- Accruals / assets
- 137.1%high accruals
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 0 good- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 17, 2014
- Director / officer changeNov 13, 2014
- Director / officer changeOct 9, 2014
- Entered a material agreement · Other material eventOct 6, 2014
- Entered a material agreementAug 28, 2014
- Director / officer changeAug 28, 2014
- Entered a material agreement · New financial obligationAug 22, 2014
- Results of operationsAug 7, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERDec 12, 2014
- 15-12BNov 28, 2014
- 4/AFORM 4/A SUBMISSIONNov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- SC 13D/ANov 19, 2014
- SC 13D/AAMENDMENT NO. 3Nov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- SC 13D/ANov 19, 2014
- 4FORM 4 SUBMISSIONNov 19, 2014
- EFFECTNov 18, 2014
- 4FORM 4 SUBMISSIONNov 18, 2014
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.